Media

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

July 20, 2017

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ — Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options with oral oncology agents, announces that the New Drug Application (NDA) for YONSA™ (abiraterone acetate) ultramicrosize tablets has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of March 19, 2018 to complete its review.